4Suppliers
11Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

Lunai Bioworks Inc. (LNAI) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

29Total relationships
5Distinct source URLs
18High confidence
0.824Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Lunai Bioworks Inc. Suppliers

TickerNameConfidenceEvidence
ONCOTELIC ONCOTELIC 90% The Series B Preferred Stock was allocated five (5) shares to Oncotelic (representing 62.5% of the Series B Preferred Stock and an aggregate Stated Value of $12,500,000)
PELERIN PELERIN 90% The Series B Preferred Stock was allocated three (3) shares to Pelerin (representing 37.5% of the Series B Preferred Stock and an aggregate Stated Value of $7,500,000)
ORANY ORANY 72% ow Renovaro Cube to control the sample preparation and medical device, thereby enabling faster commercialization analysis and quality control; and ● Expand its team to include biomedical scientists, …
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from LNAI graph: ow Renovaro Cube to control the sample preparation and medical device, thereby enabling faster commercialization ana…

Lunai Bioworks Inc. Customers

TickerNameConfidenceEvidence
CLEMANN-GROUP CLEMANN-GROUP 92% The Transaction is structured as a $20.0 million strategic investment in the Company in the form of Series B Convertible Preferred Stock
KAPOOSE-CREEK-BIO KAPOOSE-CREEK-BIO 92% During the three months ended March 31, 2026, the Company, through its wholly owned subsidiary BioSymetrics Corporation (Canada), entered into a research services agreement with Kapoose Creek Bio (th…
ORANY ORANY 72% ow Renovaro Cube to control the sample preparation and medical device, thereby enabling faster commercialization analysis and quality control; and ● Expand its team to include biomedical scientists, …
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from LNAI graph: ow Renovaro Cube to control the sample preparation and medical device, thereby enabling faster commercialization ana…
ACQUISITIONS-BIOSYMETRICS-INC ACQUISITIONS-BIOSYMETRICS-INC 62% NOTE 10 — ACQUISITIONS BioSymetrics Inc. Acquisition: On February 26, 2025, Lunai Bioworks Inc., a Delaware corporation (“ Lunai ”), entered into an Agreement and Plan of Merger (the “ Merger Agreeme…
ASSOCIATES-LLC ASSOCIATES-LLC 62% extent of effort when performing audit procedures to evaluate the reasonableness of such estimates and assumptions. Our audit procedures related to the following: ● In relation to the GediCube goodwi…
BIOSYMETRICS-CORPORATION BIOSYMETRICS-CORPORATION 62% . The investment in equity securities balance at March 31, 2026, was zero. New Accounting Pronouncements Not Yet Adopted - Recent accounting pronouncements issued by the FASB that have not yet been a…
GEDICUBE-INTL-LTD GEDICUBE-INTL-LTD 62% extent of effort when performing audit procedures to evaluate the reasonableness of such estimates and assumptions. Our audit procedures related to the following: ● In relation to the GediCube goodwi…
KAPOOSE-CREEK-BIO-INC KAPOOSE-CREEK-BIO-INC 62% oss of $2,760,570 or approximately 1,459%. The decrease in net loss was primarily due to a decrease in the change in fair value of contingent consideration of $4,260,000, a decrease in general and ad…
PLAZA-MEDICAL-OFFICE-BUILDING-LLC PLAZA-MEDICAL-OFFICE-BUILDING-LLC 62% e Agreement On June 20, 2022, the Company entered into a sublease Agreement with One Health Labs (the “Subtenant”), whereby the Subtenant agreed to lease 3,554 square feet of space currently rented b…
RENOVARO-CUBE-INTL-LTD RENOVARO-CUBE-INTL-LTD 62% have the same effect, thus complicating compliance efforts. If our operations are found to be in violation of any of such laws or any other governmental laws or regulations that apply, they may be su…

Lunai Bioworks Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
LNAI-DEBT-10738 Warrants outstanding: 3425399 90% xbrl warrant detail from xbrl 2024-06-30.
LNAI-DEBT Debt stack $204,111 90% Market cache reports total debt of $204,111.
LNAI-DEBT-10739 Xbrl Convertible 90% xbrl convertible detail from xbrl 2025-12-31.

Lunai Bioworks Inc. Acquisitions

Acquired EntityNameConfidenceEvidence
LNAI-ACQ-0001731122-26-000502 The Company entered into a binding agreement to acquire technology through a $20 million strateg... 85% The Company entered into a binding agreement to acquire technology through a $20 million strategic investment in the form of Series B Convertible Preferred Stock.

Lunai Bioworks Inc. Ownership

HolderNameConfidenceEvidence
LNAI-OWNER-STATE-STREET-CORPORATION State Street Corporation 95% 13F/ownership overlay lists State Street Corporation; shares held 35,728; ownership 0.15%; value $14,748; as of 2025-12-31.
LNAI-OWNER-NORTHERN-TRUST-CORPORATION Northern Trust Corporation 95% 13F/ownership overlay lists Northern Trust Corporation; shares held 37,402; ownership 0.15%; value $15,439; as of 2025-12-31.
LNAI-OWNER-VANGUARD-GROUP-INC Vanguard Group Inc 95% 13F/ownership overlay lists Vanguard Group Inc; shares held 497,011; ownership 2.05%; value $205,166; as of 2025-12-31.
LNAI-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC Geode Capital Management, LLC 95% 13F/ownership overlay lists Geode Capital Management, LLC; shares held 131,015; ownership 0.54%; value $54,082; as of 2025-12-31.
LNAI-OWNER-BLACKROCK-INC Blackrock Inc. 95% 13F/ownership overlay lists Blackrock Inc.; shares held 127,314; ownership 0.53%; value $52,555; as of 2025-12-31.
LNAI-OWNER-NINE-MASTS-CAPITAL-LTD Nine Masts Capital Ltd. 95% 13F/ownership overlay lists Nine Masts Capital Ltd.; shares held 24,220; ownership 0.10%; value $9,998; as of 2025-12-31.
LNAI-OWNER-CITADEL-ADVISORS-LLC Citadel Advisors Llc 95% 13F/ownership overlay lists Citadel Advisors Llc; shares held 20,632; ownership 0.09%; value $8,516; as of 2025-12-31.
LNAI-OWNER-UBS-GROUP-AG UBS Group AG 95% 13F/ownership overlay lists UBS Group AG; shares held 17,940; ownership 0.07%; value $7,405; as of 2025-12-31.
LNAI-OWNER-JANE-STREET-GROUP-LLC Jane Street Group, LLC 95% 13F/ownership overlay lists Jane Street Group, LLC; shares held 11,900; ownership 0.05%; value $4,912; as of 2025-12-31.
LNAI-OWNER-MILLENNIUM-MANAGEMENT-LLC Millennium Management Llc 95% 13F/ownership overlay lists Millennium Management Llc; shares held 166,744; ownership 0.69%; value $68,831; as of 2025-12-31.

Lunai Bioworks Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
ORANY ORANGE 100.00 1 ['customer', 'supplier']
AMZE Amaze Holdings, Inc. 50.00 2
DWTX Dogwood Therapeutics, Inc. 50.00 2
AYTU Aytu BioPharma, Inc. 50.00 2
CYCN Cyclerion Therapeutics, Inc. 50.00 2
D Dominion Energy, Inc. 50.00 2
DARE Daré Bioscience, Inc. 50.00 2
CANF Can-Fite BioPharma Ltd. 50.00 2
DFTX Definium Therapeutics, Inc. 50.00 2
CHUC Charlie's Holdings, Inc. 50.00 2
CLNE Clean Energy Fuels Corp. 50.00 2
FENC Fennec Pharmaceuticals Inc. 50.00 2
EQR Equity Residential 50.00 2
CNOB ConnectOne Bancorp, Inc. 50.00 2
CPRX Catalyst Pharmaceuticals, Inc. 50.00 2
ESS Essex Property Trust, Inc. 50.00 2
ED Consolidated Edison, Inc. 50.00 2
CORT Corcept Therapeutics Incorporated 50.00 2
BSBK Bogota Financial Corp. 50.00 2
BLTE Belite Bio, Inc 50.00 2
🔐
LNAI
Unlock LNAI Supply Chain Data
Verified relationships include:
ONCOTELICONCOTELICSupplier90%
PELERINPELERINSupplier90%
CLEMANN-GROUPCLEMANN-GROUPCustomer92%
KAPOOSE-CREEK-BIOKAPOOSE-CREEK-BIOCustomer92%
+25 more relationships locked
Subscribe — View plans →